Hillevax

Hillevax Non-Current Assets

Delisted

The Non-Current Assets of Hillevax (HLVX) as of Nov 20, 2026 is -178.35 M USD.

Non-Current Assets

-178.35 MUSD

Last updated:

Non-Current Assets of Hillevax is 2024 -178.35 M USD. Non-Current Assets of Hillevax was 2023 - USD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hillevax Stock analysis

What does Hillevax do? HilleVax, Inc. develops and commercializes novel vaccines, focusing on HIL-214, a bivalent virus-like particle (VLP) vaccine candidate for norovirus-induced acute gastroenteritis. The vaccine combines VLPs for norovirus genotypes GI.1 and GII.4 with an aluminum hydroxide adjuvant to enhance immune response. HIL-214 targets moderate-to-severe cases of norovirus infection, which causes symptoms like diarrhea, vomiting, and dehydration. The company's primary revenue stream will come from the future commercialization of HIL-214 after regulatory approval, with potential sales to healthcare providers and public health programs. Hillevax is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hillevax stock

Non-Current Assets of Hillevax is -178.35 M USD in 2024.

On Eulerpool you can find the complete historical development of Non-Current Assets Hillevax since 2006 – with annual values, charts, and detailed analysis.

Non-current assets are long-term resources not expected to be converted to cash within one year, including property, equipment, and long-term investments.

Non-Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Non-Current Assets's Hillevax historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Hillevax

All Key Metrics — Hillevax